Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

111.94 -0.01 (-0.01%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
63 64 Next >
Viking Therapeutics' Weight Loss Study Data Outperformed Novo Nordisk, Eli Lilly Studies, Analysts Say
Viking Therapeutics achieves significant weight loss in the VENTURE trial, outperforming rivals in body weight reductions. 
Via Benzinga
What Would George Soros Do? 7 Stocks the Billionaire’s Fund Bought & Sold in Q4
Dive into the insightful analysis on George Soros stocks in Q4 highlighting the foresight of an investing titan. 
Via InvestorPlace
Large US Drug Makers Highlight Indian Market For Their Blockbuster Drugs Including For Weight Loss
Eli Lilly's CEO, David Ricks, outlines plans to launch the obesity drug Tirzepatide in India next year, presenting opportunities amid competition from Novo Nordisk. Bristol Myers Squibb expands its R&D... 
Via Benzinga
Miracle Or Myth? Survey Shows Americans Doubt Ozempic, Wegovy's Weight Loss Claims
The survey, conducted from Feb. 7 to Feb. 11, found that only 35% believe these drugs will somewhat reduce obesity, while 33% think they will have little to no impact. 
Via Benzinga
EXCLUSIVE: Vivani Medical Says Weight Loss/Diabetes Implant At Par With Novo Nordisk's Famed Injectable Wegovy/Ozempic, Animal Studies Shows
Vivani Medical unveils preclinical data on NPM-115, a twice-yearly exenatide subdermal implant for weight loss. Achieving a 20% reduction in high-fat diet-induced obese mice, comparable to Novo... 
Via Benzinga
Why the quality investor may take a look at NYSE:NVO.
Should you consider NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) for quality investing? 
Via Chartmill
Balancing Dividends and Fundamentals: The Case of NYSE:NVO.
Is NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) suited for dividend investing? 
Via Chartmill
2 No-Brainer Biotech Stocks to Buy Right Now
These stocks are used to beating the market. 
Via The Motley Fool
Why Novo Nordisk and Eli Lilly Stocks Slipped Today
A competitor to Wegovy and Zepbound might appear on pharmacy shelves before long. 
Via The Motley Fool
Viking Therapeutics Skyrockets On Weight-Loss Drug Trial Results
Eli Lilly and Novo Nordisk fell modestly. 
Via Investor's Business Daily
Future Juggernauts: The Next 7 Trillion Dollar Companies to Buy Now
The seven companies discussed here have every chance of becoming the next trillion dollar stocks for investors. 
Via InvestorPlace
Amgen's Upcoming Catalysts In 2024 Set To Unlock Multi-Billion Dollar Markets, Says Goldman Sachs
Amgen's growth outlook in 2024, with updates on key programs and upcoming catalysts. Goldman Sachs sees significant opportunities despite exclusivity losses. Dive into potential market moves and... 
Via Benzinga
These 2 carnivore dining stocks gaining on the Ozempic craze
Ozempic and GLP-1 parallel the artificial intelligence (AI) mania, but it has also propelled "carnivore" restaurants like the two we feature here. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
7 Analysts Assess Novo Nordisk: What You Need To Know
Via Benzinga
Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors
Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new obesity drugs and pushing the company's shares 30% higher. 
Via Benzinga
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena
The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost. 
Via Investor's Business Daily
This Warren Buffett Stock Is On The Cusp Of Joining The $1 Trillion Club
Berkshire Hathaway is just below a $1 trillion market cap. 
Via Investor's Business Daily
DexCom: A Winner In Diabetes Management
Diabetes management and glucose monitoring solutions provider DexCom, Inc. recently released its fourth-quarter results, reporting $1.0 billion in revenue, up 27% year-over-year compared to $820... 
Via Talk Markets
1 Wall Street Analyst Thinks Novo Nordisk Stock Is Going to $140. Is It a Buy?
There's little reason to think that a big correction is in store. 
Via The Motley Fool
Obesity Solutions Like Weight Loss Drugs To Act As Catalyst For Economic Surge, Goldman Sachs Forecasts
Goldman Sachs predicts a potential 1% GDP boost from GLP-1 agonists market. Novo Nordisk and Eli Lilly lead, with analysts foreseeing 10-70 million users by 2028. AI-powered drug discovery and... 
Via Benzinga
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy. 
Via Investor's Business Daily
Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand
Indian pharmaceutical giants, including Sun Pharma and Cipla, seize the opportunity to develop affordable versions of Novo Nordisk's Wegovy weight-loss treatment. With patents set to expire by... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Move Over Magnificent 7, Say Hello to the GRANOLAS
Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods. 
Via InvestorPlace
Weight-Loss Drugs Vs. Conagra Foods: Company Optimistic Amid Shifting Consumer Demands Influenced By Hunger Suppressing
Conagra Brands' optimistic outlook at a Conference addressing concerns about weight-loss drugs impacting U.S. food companies. Executive backs positivity with Numerator data, citing an 8% rise in... 
Via Benzinga
3 Top Sectors Investment Dollars Are Pouring Into Now: February 2024
Predicting top sectors isn't easy; we usually identify them only in hindsight, but these three stock market segments are rapidly rising. 
Via InvestorPlace
3 Cheap Dividend Stocks to Snatch Up Now
Cheap dividend stocks offer rebound upside paired with an income source that is difficult to beat for most investors. 
Via InvestorPlace
Ozempic Effect: Food Industry Feels The Heat As Weight-Loss Drugs Get Popular, Investors Call For Menu Makeovers
A survey conducted by Bloomberg Markets Live revealed that nearly 75% of the 303 respondents believe that companies selling unhealthy foods should recalibrate their business models. This could involve... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Novo Nordisk Has More Than Ozempic. One of Its Other Treatments Grew 393% Last Year.
It may be best known for its diabetes treatment, Ozempic, but Novo Nordisk has a host of other blockbuster drugs, too. 
Via The Motley Fool
Wealth Generators: 3 Growth Stocks You’ll Regret Not Buying in 2024
Novo Nordisk (NVO), Caterpillar (CAT), and First Solar (FSLR) are the 3 best growth stocks you'll regret now buying in 2024! 
Via InvestorPlace
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
63 64 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback